U.S. Dry Eye Syndrome Treatment Market Size & Outlook
Related Markets
U.S. dry eye syndrome treatment market highlights
- The U.S. dry eye syndrome treatment market generated a revenue of USD 2,446.2 million in 2024 and is expected to reach USD 3,470.0 million by 2030.
- The U.S. market is expected to grow at a CAGR of 6% from 2025 to 2030.
- In terms of segment, evaporative dry eye syndrome was the largest revenue generating type in 2024.
- Evaporative Dry Eye Syndrome is the most lucrative type segment registering the fastest growth during the forecast period.
Dry eye syndrome treatment market data book summary
| Market revenue in 2024 | USD 2,446.2 million |
| Market revenue in 2030 | USD 3,470.0 million |
| Growth rate | 6% (CAGR from 2025 to 2030) |
| Largest segment | Evaporative dry eye syndrome |
| Fastest growing segment | Evaporative Dry Eye Syndrome |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Evaporative Dry Eye Syndrome, Aqueous Deficient Dry Eye Syndrome |
| Key market players worldwide | Novartis AG ADR, AbbVie Inc, Sun Pharmaceutical Industries, Santen Pharmaceutical Co Ltd, Johnson & Johnson, Otsuka Pharmaceutical, OASIS Medical, Bausch & Lomb Corp, AFT Pharmaceuticals, Oyster Point Pharmaceuticals |
Other key industry trends
- In terms of revenue, U.S. accounted for 38.9% of the global dry eye syndrome treatment market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. dry eye syndrome treatment market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 286.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Dry Eye Syndrome Treatment Market Scope
Dry Eye Syndrome Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Oyster Point Pharmaceuticals | View profile | 101-250 | San Francisco, California, United States, North America | https://oysterpointrx.com/ |
| AFT Pharmaceuticals | View profile | 51-100 | Takapuna, Auckland, New Zealand, Oceania | http://www.aftpharm.com/ |
| OASIS Medical | View profile | 101-250 | Glendora, California, United States, North America | http://oasismedical.com/ |
| Santen Pharmaceutical Co Ltd | View profile | 1807 | Grand Front Osaka Tower A, 4-20 Ofuka-cho, Kita-ku, Osaka, Japan, 530-8552 | http://www.santen.co.jp |
| Otsuka Pharmaceutical | View profile | 251-500 | Tokyo, Tokyo, Japan, Asia | https://www.otsuka.co.jp/en/ |
| Sun Pharmaceutical Industries | View profile | 10001+ | Mumbai, Maharashtra, India, Asia | http://www.sunpharma.com |
| Bausch & Lomb Corp | View profile | 13300 | 520 Applewood Crescent, Vaughan, ON, Canada, L4K 4B4 | https://www.bausch.com |
| AbbVie Inc | View profile | 50000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | http://www.abbvieinvestor.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
| Johnson & Johnson | View profile | 134400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | https://www.jnj.com |
U.S. dry eye syndrome treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to dry eye syndrome treatment market will help companies and investors design strategic landscapes.
Evaporative dry eye syndrome was the largest segment with a revenue share of 82.48% in 2024. Horizon Databook has segmented the U.S. dry eye syndrome treatment market based on evaporative dry eye syndrome, aqueous deficient dry eye syndrome covering the revenue growth of each sub-segment from 2018 to 2030.
The prevalence of dry eye syndrome in the U.S. is expected to grow over the forecast period. According to National Health and Wellness Survey, it is estimated that around 6.8% of the total population in the U.S. is diagnosed with dry eye disease. The prevalence of disease increases with an increase in age, wherein the prevalence is 2.7% in the age group of 18-34 and around 18.6% in those above 75 years of age.
Moreover, it is observed that the prevalence is higher in women than in men, with the prevalence being 8.8% in women and 4.5% in men. Furthermore, with the rising geriatric population, the prevalence is expected to rise as this population group is more susceptible to dry eye diseases. According to the U.S. Census Bureau, in 2020, over 56 million individuals living in the U.S. were 65 years of age and older.
The geriatric population is expected to rise to 73.1 million by 2030 and 85.7 million by 2050. In addition, around 1 million people in the U.S. suffer from contact lens complications annually, which also include dry eye syndrome. All these factors contribute to increasing prevalence of the condition in the population.
Reasons to subscribe to U.S. dry eye syndrome treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. dry eye syndrome treatment market databook
-
Our clientele includes a mix of dry eye syndrome treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. dry eye syndrome treatment market , including forecasts for subscribers. This country databook contains high-level insights into U.S. dry eye syndrome treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. dry eye syndrome treatment market size, by drug, 2018-2030 (US$M)
U.S. Dry Eye Syndrome Treatment Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
